Posts by Sandra Ansanay-Alex
A gene could prevent Parkinson’s disease
A mutation in the Fer2 gene causes motor deficiencies in flies The laboratory of Emi Nagoshi, Professor in the Department of Genetics and Evolution at the UNIGE Faculty of Science, uses the fruit fly, or Drosophila, to study the mechanisms of dopaminergic neuron degeneration. Her group is particularly interested in the Fer2gene, whose human…
Read MoreBioArk Monthey is expanding
A third building is under construction at BioArk Monthey Until now, BioArk has offered 6,000m2 of space between its first two buildings, BioArk I and II. BioArk III, with some 5,000m2 of floor space, including several 850m2 platforms, will house startups and companies active in the life sciences sector. The site offers unique multi-functional facilities,…
Read MoreCeidos revolutionises cell culture
The BioArk startup received a CHF 100 000 loan from FIT Advanced therapy medicinal products (ATMPs) are active medicines that are based on genes, tissues, or cells. They offer groundbreaking new opportunities for the treatment of cancers, degenerative diseases, genetic disorders, and injury. But producing them is a challenge and very expensive. Leonard Barras and…
Read MoreSuperlab Suisse Lausanne
A coworking space designed for scientists Located in the Biopôle in Lausanne, Superlab Suisse offers ready to move in laboratory spaces. Superlab Suisse’s «Lab as a Service» business concept includes innovatively designed laboratory facilities, state-of-the-art equipment, professional and concierge services, as well as financing support for companies in the biotech, pharma, and medtech sectors.…
Read MoreUNIGE: Fighting breast cancer cells growth
A low rate of a specific protein triggers tumors development. A UNIGE team found the counter-attack In about 2/3 of breast cancers, the hormone estrogen facilitates tumor growth. A tamoxifen-based treatment inhibits tumors’ estrogen receptors to prevent their development. But 40 % of treated patients develop a resistance to the molecule. The laboratory of…
Read More$11 million for EPFL spin-off Leman Biotech
A protein that boosts the immune system can cure 90% of cancer in mice Immunotherapy, which aims to boost the patient’s immune system to fight cancer, has no effect in two out of three cases. After a while, T lymphocytes, the main players against cancer cells, become exhausted. To give them a new lease…
Read MoreGSK’s new company Haleon will have a site in Nyon
The pharmaceutical group GlaxoSmithKline creates Haleon, a new company from the separation of its consumer healthcare business. This entity will have a site in the commune of Prangins, part of the district of Nyon. The site currently employs 1,000 people in Prangins and produces 252 million units per year, including the medicines Voltaren and Otrivin.…
Read MoreNeo Medical raises $20 million for its AR technology for spine surgery
Swisscom Ventures is the lead investor in this round. The Vaud-based company will use the new funds to accelerate the commercial deployment of its artificial intelligence-supported augmented reality platform for spinal surgery. With a focus on the US market. Called Advise, the technology “provides surgeons with real-time intraoperative augmented reality (AR) visibility for the first…
Read MoreINTERVIEW : Massimo Nobile
🔺 Massimo Nobile, SwissBiotech Center CEO, explains how digital and life sciences are converging to create new medicines and treatments.
Read MoreMindMaze secures a $105 million financing round
After a banner-year, the Lausanne-based company MindMaze secures $105 Million Financing, led by Concord Health Partners, and initiates American Hospital Association Partnership MindMaze is a pioneer in the multibillion-dollar digital neurotherapeutics market and develops therapeutic solutions for a wide spectrum of neurological diseases. The financing was led by Concord Health Partners (“Concord”), a US-based…
Read More